About 195,000 results
Open links in new tab
  1. Ingrezza (valbenazine) Reviews & Ratings by Patients – WebMD

    I have an extreme form of Tardive Dystonia (full body, occasionally resulting in complete disability) with Functional Movement Disorder. Initially I was diagnosed with garden-variety Tardive …

    • Reviews: 12
    • Ingrezza Reviews & Ratings - Drugs.com

      Ingrezza User Reviews & Ratings Ingrezza has an average rating of 6.0 out of 10 from a total of 21 reviews on Drugs.com. 52% of reviewers reported a positive experience, while 38% …

    • New Review on VMAT2 Inhibitors and Ingrezza for Treatment of …

      3 days ago · Inhibition of VMAT2 is thought to inhibit dopamine release, affecting movement control. With inhibited dopamine release, Ingrezza is believed to reduce excessive dopamine …

    • An Evidence-Based Update on Anticholinergic Use for Drug-Induced ...

      Although antipsychotics are highly effective for many conditions and have positive impacts on patients’ lives, they can have significant side effects. Moreover, greater antipsychotic exposure …

    • Neurocrine Biosciences Announces Publication of Landmark

      1 day ago · Among key insights, the review highlights the distinct profiles of VMAT2 inhibitors approved for tardive dyskinesia and presents unique attributes of INGREZZA: selectivity to …

    • TD Patient Cases | INGREZZA® (valbenazine) capsules | HCP

      Previously treated with anticholinergic for drug-induced movement disorder (DIMD) Diagnosed with TD approximately 1 year prior to treatment with INGREZZA Presented with predominantly …

    • Ingrezza Side Effects: Side Effects and How to Manage Them - Healthline

      Apr 23, 2025 · Get the facts about Ingrezza side effects and how to manage them. Ingrezza (valbenazine) is a prescription drug used to treat tardive dyskinesia and other movement …

    • Their impact can erode patient trust, result in less medication adherence, lead to poor quality of life and increased morbidity and mortality.2 Key features of common antipsychotic-induced …

    • What Class of Drug is Ingrezza? A VMAT2 Inhibitor Explained

      4 days ago · Ingrezza is a VMAT2 inhibitor, a specific drug class that regulates dopamine to treat movement disorders. Learn its mechanism, uses for tardive dyskinesia and Huntington's, and …

    • Perform regular screenings for movement disorders in patients taking antipsychotics in order to diagnose and initiate treatment as early as possible Utilize clinical assessment tools to obtain …